Antibody-drug conjugate (ADC) developers in China are mulling over ways to put up a fight for future domestic market share, given that Daiichi Sankyo Co., Ltd./AstraZeneca PLC’s blockbuster ADC Enhertu (trastuzumab deruxtecan) is set to make inroads in the country over the coming months.
As evidenced by recent partnerships forged with US drug makers to out-license global rights to Claudin 18.2-targeted ADC candidates, some...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

